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Objective: Review the impact of StAR (STARD1) mutations on steroidogenesis and
fertility in LCAH patients. Examine the endocrine mechanisms underlying the pathology
of the disorder and the appropriate therapy for promoting fertility and pregnancies.
Design: Published data in the literature and a detailed 38-year follow-up of two sibling
LCAH patients. Molecular structure and modeling of the STARD1 L275P mutation.
Setting: University hospital.
Patients: Patient A (46,XY female phenotype) and patient B (46,XX female) with LCAH
bearing the L275P mutation in STARD1.
Interventions: Since early-age diagnosis, both patients underwent corticoid
replacement therapy. Patient A received estrogen therapy at pubertal age. Clomiphene
therapy was given to Patient B to induce ovulation. Pregnancies were protected with
progesterone administration.
Main Outcome Measures: Clinical and molecular assessment of adrenal and gonadal
functions.
Results: Both patients have classic manifestations of corticosteroid deficiency
observed in LCAH. Time of onset and severity were different. Patient A
developed into a female phenotype due to early and severe damage of Leydig
cells. Patient B started a progressive pubertal development, menarche and
regular non-ovulatory cycle. She was able to have successful pregnancies.
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Conclusions: Understanding the molecular structure and function of STARD1 in
all steroidogenic tissues is the key for comprehending the heterogeneous clinical
manifestations of LCAH, and the development of an appropriate strategy for the induction
of ovulation and protecting pregnancies in this disease.
Keywords: LCAH, spontaneous puberty, fertility, pregnancy, steroidogenic acute regulatory protein (StAR,
STARD1), cholesterol, molecular structure, therapy
INTRODUCTION
Classical lipoid congenital adrenal hyperplasia (LCAH), which
was originally described by Prader and Siebenmann (1957)
is a severe form of congenital adrenal hyperplasia inherited
as an autosomal recessive disease. Patients bearing this
disorder show an impaired production of glucocorticoids,
mineralocorticoids, and sex steroids. Their basal levels of
adrenocorticotropin (ACTH) and plasma renin activity (PRA)
are high with no steroidal response to ACTH, or human
chorionic gonadotropin (hCG) treatment. Signs of adrenal
insufficiency and hyperpigmentation occur in phenotypic female
infants regardless of the karyotype (Bose et al., 1996).
In LCAH, the destruction in early fetal life of Leydig cells
of 46,XY subjects, by the toxic effect of stored cholesterol
and derivatives, eliminates testosterone biosynthesis and
normal virilization. In such cases, external genitalia are female
with blind vaginal pouch and absence of cervix, uterus, and
fallopian tubes due to undamaged Sertoli cells producing
the Müllerian inhibitory hormone. Occasionally reported
development of Wolffian ducts testifies for the presence of
testosterone synthesis early in fetal life (Ogata et al., 1989).
When adequately treated, 46,XX subjects may undergo
spontaneous puberty, feminization and even cyclic vaginal
bleeding (Matsuo et al., 1994; Bose et al., 1997; Fujieda et al.,
1997). Despite the presence of sufficient amounts of estrogens
to produce secondary sexual development and endometrial
growth, progesterone levels remain undetectable, indicating
that the periodic vaginal bleeding is of a non-ovulatory
nature (Fujieda et al., 1997). Thus, affected individuals are
all phenotypically female with a severe salt-wasting crisis and
hyperpigmentation and may die shortly after birth unless
treated with steroid-replacement therapy (Hauffa et al.,
1985). Non-classical LCAH has also been reported: Affected
individuals present with a phenotype of late onset adrenal
insufficiency with only mild or minimally disordered sexual
development (Baker et al., 2006; Sahakitrungruang et al.,
2010).
Abbreviations: StAR, steroidogenic acute regulatory protein (STARD1);
LCAH, lipoid congenital adrenal hyperplasia; P450scc, cytochrome P450
side chain cleavage; Testo, testosterone; Andro, androstenedione; DHEA,
dehydroepiandrosterone; Prog, progesterone; E2, 17β-estradiol; LH,
luteinizing hormone; FSH, follicular stimulating hormone; 17 OH-Prog,
17 hydroxy-progesterone; 17 OH-Preg, 17 hydroxy-pregnenolone; ACTH,
adrenocorticotropin; hCG, human chorionic gonadotropin; PRA, plasma renin
activity; PCR, polymerase chain reaction; PMSG, post-menopausal stimulating
gonadotropin; IVF; in vitro fertilization; PPROM, premature preterm rupture of
membranes.
Because mitochondria from affected adrenal and gonads fail
to transform cholesterol to pregnenolone, it has been postulated
for many years that LCAH disease was due to a defect in the
cholesterol side chain cleavage enzyme complex cytochrome
P450 (P450scc) (Degenhart et al., 1972; Koizumi et al., 1977;
Matteson et al., 1986) which is the first step in steroidogenesis:
The conversion of cholesterol to pregnenolone. In searching
for such defect, Lin et al. (1991), Sakai et al. (1994) and
Fukami et al. (1995) found no mutations in the CYP11A1
gene of affected individuals. However, mutations in CYP11A
gene were subsequently reported resulting in indistinguishable
clinical and hormonal phenotypes when compared to LCAH
cases (Tajima et al., 2001; Katsumata et al., 2002; Hiort
et al., 2005). In addition, these patients do not have the
massive adrenal hyperplasia that characterizes LCAH (Miller,
2016).
With the discovery of STARD1 (STeroidogenic Acute
Regulatory) protein (Clark et al., 1994), the leading cause of
LCAH was then attributed to mutations in that protein (Lin
et al., 1995; Bose et al., 1996). STARD1 is produced in the
cytoplasm and mediates the biosynthesis of steroid hormones
by controlling the transfer of cholesterol from the outer
mitochondrial membrane (OMM) to the inner mitochondrial
membrane (IMM) where P450scc is located (Farkash et al., 1986;
Geuze et al., 1987). Moreover, numerous mutations disrupting
STARD1 activity were found in the carboxyl-terminal of the
protein (Lin et al., 1995; Bose et al., 1996; Bhangoo et al., 2005,
2006) suggesting that this is a biologically important domain.
Another crucial domain for STARD1 is the cholesterol binding
pocket which contains a putative salt bridge between Glu169 and
Arg188 (Mathieu et al., 2002a). Other clinical STARD1 mutations
are found at the binding site, in particular Glu169 andMet225, and
they lead to LCAH (Miller, 1997).
In the absence of STARD1, steroidogenesis proceeds, for
a temporary period, at about 14% of the STARD1 induced
level (Lin et al., 1995; Tee et al., 1995; Bose et al., 1996;
Miller, 1997; Khoury et al., 2006a). The pathogenesis of the
different manifestations of LCAH involves STARD1-dependent
and STARD1-independent steps of steroidogenesis (Bose et al.,
1996; Miller, 1997). The STARD1-dependent phase would be the
loss of the protein activity leading to a decrease of more than 80%
of adrenal and gonad steroidogenesis. The STARD1-independent
stage is characterized by a destruction of the steroidogenic
capacity due to the accumulation of cholesterol, cholesterol esters
and oxidation products. This engorges the cells and damages
its cytoarchitecture through both physical displacement and
biochemical actions.
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We have previously communicated the cases of LCAH in two
children (46,XX and 46,XY) of a French Canadian family due to
a homozygous L275P STARD1 mutation (Khoury et al., 2004).
Furthermore, ovulation and pregnancies in the 46,XX patient
were possible with Clomiphene stimulation and progesterone
administration during the first trimester (Khoury et al., 2006b,
2009). Here, we review data collected over a three-decade
follow-up of these patients focusing on their clinical evolution,
gonadal function, puberty and fertility. Finally, the STARD1
mechanism of action and the impact of the clinical mutants on
the protein’s structure/activity will be addressed. An informed
consent form was signed by all participants for blood sampling
and analysis, and studies were approved by the institutional
“Comité d’éthique de la recherche en santé chez l’humain du
CHUS”.
PATIENT A (46,XY KARYOTYPE)
Patient A was born in summer 1977 after 41 weeks of normal
gestation, weighing 3960 g and measuring 53 cm (Khoury et al.,
2004). External genitalia were described as normal female
phenotype with bilateral inguinal hernia. This was surgically
repaired at the age of 5 weeks with no complications. Both
gonads observed during surgery were pushed into the abdomen.
At the age of 11 months, the patient suffered from gastroenteritis,
hyperthermia, and dehydration. Blood pressure was 100/50, heart
rate 120/min, and respiratory rate 24–28/min. Blood glucose
was 3.8mmol/L, sodium 121mmol/L, chloride 93mmol/L,
potassium 5.4mmol/L, and serum bicarbonate was 7mmol/L.
Intravenous fluid and glucose were administered to correct
this situation. Four days after the cessation of the intravenous
therapy, electrolytes disturbance and metabolic acidosis
relapsed (sodium 126mmol/L, chloride 103mmol/L, potassium
6.3mmol/L, sodium bicarbonate 14mmol/L, and blood glucose
4.6mmol/L). Intravenous rehydration was restarted. Physical
examination was normal except for generalized and moderate
hyperpigmentation, hypertrichosis on arms and on the lower
part of her back. The external genitalia corresponded to those of
a normal female with normal clitoris and vaginal orifice. There
were no palpable gonads in the inguinal region and the scar of
the previous surgical procedure appeared normal.
Adrenal Function
At the age of 11 months, serum cortisol was 640 nmol/L at 8 h
00 and 361 nmol/L at 16 h 00 (N = 165–635 nmol/L); serum
aldosterone was respectively 641 and 319 pmol/L (N = 168–
2570 pmol/L) and plasma renin activity was 11.9 ng/ml/s at
16 h (N < 4.17 ng/ml/s), and urine pregnanetriol 0.0 µmol/d
(N = 0.06–0.6). Further investigations showed that serum
cortisol, aldosterone as well as urinary pregnanetriol did not
respond to intramuscular ACTH stimulation for 3 days (Table 1).
Substitution therapy with mineralocorticoid (fludrocortisone
acetate) and glucorticoid (cortisone acetate) was then started.
Four months later, we decided to stop cortisone acetate to obtain
more data on her glucocorticoid secretion.
For the following 20 months, the child was growing well
(50 percentile for height and weight) and has no specific
symptoms. From 35 to 41 months of age, the patient was
admitted to the hospital for 3 episodes of hypoglycemia and
acidosis during infectious illnesses. Blood glucose was 1.4–
4.0mmol/L, electrolytes were normal with high renin activity
and elevated urinary sodium. Basal steroid hormones (while
receiving fludrocortisone acetate 0.025mg every 12 h) revealed
low cortisolemia∗ 69 and 8.28 nmol/L at 8 and 16 h respectively,
normal aldosterone∗∗ 737 and 208 pmol/L, 17 OH-progesterone
0.15 nmol/L (N = 0.1–2.7), DHEA 0.69 nmol/L (N = 0.38–
2.52), DHEA-S 0.54 µmol/L (N = 0.13–0.54) testosterone
0.1 nmol/L (N = 0.07–0.9), and ACTH 33 pmol/L (N = 2–11).
ACTH stimulation test was repeated at that time (intramuscular
injections of ACTH-Gel 25 IU/m2 every 12 h × 5 days)
under replacement therapy with fludrocortisone acetate 0.025mg
every 12 h and Dexamethasone 0.25mg every 8 h. The higher
values of blood cortisol and aldosterone obtained during this
stimulation was 19.3 and 263 pmol/L respectively, urinary
free cortisol∗∗∗ was < 5.5 nmol/day and pregnanetriol∗∗∗∗
0.11 µmol/day at that moment. The result of previously
ordered blood karyotype revealed the suspected 46,XY. Then
clinical, biochemical and genetic studies confirmed the suspected
diagnosis of what was believed at that time as 20,22 desmolase
deficiency. Substitution therapy with fludrocortisone acetate
and hydrocortisone continues, doses were regularly adjusted
according to clinical symptoms, blood glucose and electrolytes as
well as serum level of ACTH and PRA in addition to observations
of growth and bone maturation.
Normal basal values from 2–5 years:
∗ Cortisol 166–525 nmol/L (mean 1 after ACTH stimulation
400 nmol/L)
∗∗ Aldosterone 83–971 pmol/L (mean 1 after ACTH
stimulation 500 pmol/L)
∗∗∗ Urinary free cortisol 8.28–24.8 nmol/d
∗∗∗∗ Urinary pregnanetriol< 1.5 µmol/d
Radiological Investigations
At the moment of her first admission, at 11 months of age,
the IV pyelography was normal. Several pelvic and abdominal
echographies were performed from the age of 3 6/12 to 13
years. These showed no uterus, no visible gonads and no adrenal
hypertrophy, the bone age was always significantly delayed
(growth curve not shown).
Gonadal Function
FSH, LH and different androgens were measured at regular
intervals from the age of∼3 years until the patient was 13 year old
(Table 2). As can be seen, the levels of serum androstenedione,
dehydroepiandrosterone, total and free testosterone were low to
not detectable. hCG stimulation test (intramuscular injections
4000 IU/day for 5 days) was performed at the age of 13
years (while the patient was receiving fludrocortisone acetate
and Dexamethasone). As shown in Table 2, hCG stimulation
did not increase circulating levels of 17 OH-pregnenolone, 17
OH-progesterone, DHEA, androstenedione, and total and free
testosterone.
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TABLE 1 | Patient A.
Dates Serum cortisol nmol/L (165–635) Serum aldosterone pmol/L (168–2520) Plasma renin ng/L/s (<4.17) Urine pregnanetriol µmol/day (0.06–0.6)
Day 2 966 670 19.46 0
Day 1 634 621 22.2 <0.03
Day 0 739 474 11.95 <0.03
Day 3 811 244 15.29 <0.03
Day 4 497 357 13.34 <0.09
ACTH stimulation test: Injection of ACTH-Gel 25 IU/m2 /q 12 h/3 days During this test, the patient received NaCl 70 meq/d, the serum sodium was 120–131 mmol/L, potassium 6.0–6.9
mmol/L and urinary sodium 51–64 mmol/L, at 8 and 16 h respectively. Age of patient A, 11 months.
TABLE 2 | Patient A.
Hormones age FSH IU/L LH IU/L 17 OH-Preg 17 OH-Prog DHEA nmol/L Andro nmol/L Testo (total) Testo (free)
nmol/L nmol/L nmol/L nmol/L
∼3 years – – − 0.15 0.69 − 0.1 –
∼4 years – – − − < 0.35 < 0.3 < 0.35 –
5 10/12 years 3.9 < 2.7 − − 1.73 < 0.3 < 0.35 –
6 7/12 years 13.8 < 5 − − 2.08 < 0.7 < 0.35 –
7 6/12 years 8.6 < 5 − − − − < 0.35 –
8 years 23 < 5 − − − − < 0.35 -
8 9/12 years 11.8 5.1 − − − − < 0.35 < 0.6
10 4/12 years 11.6 < 2 − − − − < 0.35 < 2
12 6/12 years 4.6 < 0.5 − − < 1.7 < 0.3 < 0.7 < 3
h
C
G
(IM
)
4
0
0
0
IU
/d
X
5
d
a
ys
D 0 33.2 1.8 < 0.16 < 0.3 < 1.5 < 0.3 < 0.7 < 1.0
D 3 – – < 0.16 < 0.3 < 1.5 < 0.3 < 0.7 –
D 4 – – < 0.16 < 0.3 < 1.5 < 0.3 < 0.7 –
D 6 – – < 0.16 < 0.3 < 1.5 < 0.3 < 0.7 < 2.1
T, total; F, free; D, day; –, not available. Normal values are indicated for different ages:
FSH: Prepubertal 0.26–3 IU/L, puberty Tanner II, III 0.6–10.9 IU/L.
LH: Prepubertal 0.02–0.3 IU/L, puberty Tanner II, III 0.2–5.0 IU/L.
17-OH pregnenolone: Puberty Tanner II, III 0.6–10.9 nmol/L.
17-OH progesterone: Prepubertal 0.09–2.7 nmol/L, puberty Tanner II, III 0.3–3.9 nmol/L.
DHEA: 2–5 years 0.38–2.52 nmol/L, 6–10 years 0.9–5.3 nmol/L, puberty Tanner II, III 0.87–10.5 nmol/L.
Androstenedione: 1–10 years 0.18–1.78 nmol/L, puberty Tanner II, III 0.6–2.87 nmol/L.
Testosterone (total): 3–10 years 0.07–0.66 nmol/L, puberty Tanner II, III 0.63–11.2 nmol/L.
Testosterone (free): Prepubertal 0.52–2.0 pmol/L, adult male 180–971pmol/L.
Gonadal function of Patient A measured at different interval from age 3 to 13 years old.
Gonadal Histology
A laparotomy was performed at the age of 13 5/12 years: The
left gonad (3 × 1.5 × 1 cm) was removed. The exploration of
the right side was negative and showed no Müllerian or Wolffian
structures. The histology of the removed gonad is illustrated in
Figure 1. Worth noticing is the atrophy and hyalinization of
the seminiferous tubules, the presence of some germinal cells
without spermatogonia, the presence of some Sertoli cells and the
important engorgement of Leydig cells with fat.
Growth
The patient’s growth velocity decreased regularly from the age
of 10 years until she was 14 year old. Bone age was always
significantly delayed (curve not shown). The thyroid function
and growth hormone secretions were normal. Progressive ethinyl
estradiol therapy was started at the age of 14 leading to a gradual
pubertal development (good breast development, moderate
pubic hair) and an increase of the growth rate. Final adult height
was in the normal mid-parental range.
PATIENT B (46,XX KARYOTYPE)
Patient B was born in spring 1979 (Koizumi et al., 1977;
Khoury et al., 2004). She had skin hyperpigmentation since the
age of 1.5 months. At 4.5 months, she was hospitalized for
fever, anorexia, fatigue and weight loss, and was treated with
antibiotics (pharyngitis) for 10 days. Furthermore, she suffered
from somnolence, vomiting and dehydration with hyponatremia
and hyperkalemia (Khoury et al., 2009).
Adrenal Function
The endocrine investigations revealed a low/normal serum
cortisol 174 nmol/L (N = 77–635), low/normal aldosterone
138.7 pmol/L (N = 166–1970) and renin activity 3.3 ng/L/s
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FIGURE 1 | Histology of the removed gonad. (A) Testis in low magnification: atrophic seminiferous tubules (1). Hyaline thickening of the basal membranes (2).
Hyperplasia and clarification of the Leydig cells (3). (B) Testis in higher magnification: atrophic seminiferous tubules (1) containing Sertoli cells in the absence of
spermatogonia. Lipid overload of the Leydig cells (2).
TABLE 3 | Patient B.
Time Serum cortisol Serum aldosterone Plasma renin
nmol/L (166–525) pmol/L (139–1498) ng/L/s (<2.8)
Day 1 18.2 136 0.88
Day 0 5.52 161 6.47
Day 2 8.28 136 3.27
Day 4 13.8 180 5.36
ACTH stimulation test: Injection of ACTH-Gel 25 IU/m2/12 h/3 days. Age of Patient B, 21
months. Normal values are in parentheses.
(N < 4.17). The urinary pregnanetriol was 0.59 µmol/day (N
= 0.06–0.6). The ACTH stimulation (IM injections of ACTH-
Gel 25 IU/m2 q 12 h. × 3 days) resulted of very small increases
in cortisol (220 nmol/L) and aldosterone (277.4 pmol/L). She
was growing well with no specific symptoms while treated
only with fludrocortisone acetate 0.025mg bid, up to the age
of 15 months. From that age to 21 months she suffered 3
episodes of hypoglycemia during a varicella illness and otitis
media. Her serum cortisol level was 8.28 nmol/L (N = 166–
690), serum aldosterone and plasma renin activity were 141.3
pmol/L (N = 139–1498) and 0.67 ng/L/s (N < 2.8) respectively.
Then Dexamethasone 0.25mg p.o. every 8 h was added to
fludrocortisone acetate before to undergo her second ACTH
stimulation test. Results illustrated in Table 3 indicate a very
low basal cortisol and incapacity of the zona fasciculata-
reticularis to respond to ACTH stimulation; the same table
shows low level of aldosterone with no response of the zona
glomerulosa to ACTH stimulation. Consequently, the doses of
glucocorticoids (Dexamethasone changed for hydrocortisone)
and fludrocortisone acetate, were adjusted regularly during all the
next years, according to her clinical evolution, blood glucose and
electrolytes, as well as plasma ACTH and renin activity.
Gonadal Function
The patient’s serum levels∗ of FSH and LH were normal up to
puberty. Serum levels of 17 OH-Prog, DHEA, androstenedione,
and testosterone were very low. Plasma ACTH varied from
43–4.6 pmol/L during that period. She started thelarche and
pubarche at the age of 11 7/12 and 12 years, respectively.
The hypophyso-gonadal function was previously summarized
(Khoury et al., 2009). A spontaneous normal menarche started
at the age of 14 2/12 years. The menstruations were regular
with no dysmenorrhea. The basal temperature registered between
21 and 24 years indicated a monophasic non-ovulatory curve.
Shortly after a Clomiphene stimulation, circulating 17β-estradiol
level increased from 703 to 1428 pmol/L and progesterone level
increased from 3.4 to 9.4 nmol/L (Khoury et al., 2004).
∗Normal prepubertal values: FSH 1.0–4.2 IU/L, LH 0.02–
0.18 IU/L, 17-OH progesterone 0.09–2.72 nmol/L, DHEA
0.4–6.6 nmol/L, androstenedione 0.28–1.75 nmol/L, testosterone
0.07–0.35 nmol/L.
Radiological Investigations
An abdominal and pelvic echography was performed at the age
of 2 5/12 years. It revealed a normal uterus and ovaries. Adrenal
glands have no particular aspect. This examination was repeated
at 11 1/12 years and 12 3/12 years and showed a prepubertal
uterus and normal ovaries with small follicles. A small delay of
bone age was noted at different ages.
Growth
Regular growth was observed. Peak height velocity began around
the age of 13 years. Final adult height was in the normal mid-
parental range.
Fertility Studies and Childbirth
Clomiphene stimulation, to increase gonadal activities and
induce ovulation, was started at the age of 25 years. First
pregnancy occurred at the age of 25 4/12 years, unfortunately
interrupted by spontaneous abortion 6 weeks later (Khoury
et al., 2009). A second pregnancy (quadruple) was initiated
later on with Clomiphene stimulation, and was protected with
progesterone supplementation at the 17th day of the cycle. One
fetus was naturally lost at 7 weeks of gestation and one feticide
was done 1 ½ weeks later, so progesterone was continued up to
the 25th week of gestation. In October 2005, two normal boys
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were born prematurely. This first child delivery was previously
communicated in an international meeting in 2006 (Khoury
et al., 2006b). At 28 years old, a third pregnancy initiated with
Clomiphene stimulation, and progesterone was taken from the
17th day of the cycle up to the 17th week of gestation. After 36
weeks of normal gestation, a female child was born in October
2008 (Khoury et al., 2009).
Molecular Biology Studies
Genomic DNA was extracted from the gonadal tissue of patient-
A. The seven exons of the STARD1 gene were PCR-amplified
using primers and conditions previously described (Bose et al.,
1996) and PCR products were sequenced. A mutation was found
in exon 7 which was located at the amino acid residue 275,
a leucine being substituted by a proline. Genomic DNA was
subsequently extracted from the blood leukocytes of the two
patients, their two parents and a normal individual. The exon
7 was analyzed for each individual. For the mutation L275P,
the control was +/+, the two parents were +/−, and the two
children were−/− (Figure 2).
COS-1 cells were used to determine STARD1 activity and
quantification. Figure 3A shows results obtained by western
blotting analysis, and Figure 3B shows that the L275P mutant
activity was 87% impaired compared to wild type (Khoury et al.,
2004).
MECHANISM OF CHOLESTEROL
TRANSFER BY STARD1
In order to better explain how clinical mutations affect
steroidogenesis, we will discuss the mechanism of action of
STARD1 at the molecular level. STARD1 delivers cholesterol
from the outer to the inner membrane of mitochondria is poorly
understood. STARD1 may act as a sterol transfer protein and
enhance sterol desorption from the outer to the inner side
of mitochondria (Kallen et al., 1998; Petrescu et al., 2001). In
this model STARD1 is directed to the mitochondria via its N-
terminus recognition sequence and then, utilizing C-terminal
sequences, produces as yet unidentified alterations in the OMM
that results in the transfer of cholesterol to the inner side. It is
established that STARD1 acts on the OMM and that its level
of activity is proportionate to the time it remains at that site
(Arakane et al., 1998; Bose et al., 2002).
MLN64, a protein involved in cholesterol transfer in
malignant breast cancer, has a significant homology to the
C-terminal region of STARD1 and can promote cholesterol
transfer (Watari et al., 1997). The C-terminus of STARD1
contains the StAR-Related Lipid Transfer (START) domain
which is conserved across a large family of proteins including
MLN64 and STARD1 (Ponting and Aravind, 1999; Stocco, 2000;
Tsujishita and Hurley, 2000). START domain in MLN64 is
homologous to the START domain of the STARD1 protein.
Both, functionally similar, are able to bind cholesterol in a 1:1
ratio (Tsujishita and Hurley, 2000; Petrescu et al., 2001). It was
first proposed that STARD1 acts as a cholesterol shuttle for
transferring cholesterol to the IMM via a hydrophobic tunnel
FIGURE 2 | DNA sequencing. Genomic DNA was extracted from the blood
of two patients, their two parents and a normal individual as control (A) using
the Invitrogen DNAzol BD reagent. The seven exons of the STARD1 gene were
PCR and sequenced. A mutation was found in exon 7. For exon 7
oligonucleotides used for PCR were (5′ to 3′)
ATGAGCGTGTGTACCAGTGACG, (5′ to 3′) CCTGGCAGCCTGTTTGTGATAG;
the annealing temperature was 60◦C and the reaction processed for 30
cycles. The PCR products were sequenced. The mutation found in exon 7 was
located at the amino acid residue 275, a leucine being substituted by a proline.
The two parents (B,C) were +/−, and the two children (D,E) were −/−.
revealed by the crystal structure of MLN64-START (Tsujishita
and Hurley, 2000), but the exact mechanism by which STARD1
releases cholesterol to the IMM is unknown (Stocco, 2001).
According to computer homology models based on MLN64
structure, STARD1 does not contain a tunnel, but a hydrophobic
pocket that can accommodate one molecule of cholesterol
(Mathieu et al., 2002a,b; Baker et al., 2005; Yaworsky et al., 2005;
Murcia et al., 2006; Lavigne et al., 2010; Thorsell et al., 2011;
Létourneau et al., 2014, 2015); the STARD1 crystal structure
corroborates this hydrophobic pocket. Several mutations that
result in LCAHwere mapped onto the MLN64-START structure,
in positions residing within the hydrophobic tunnel; these
mutations would destabilize the tunnel. In parallel, the residues
Glu169, Met225, and Leu275 are part of STARD1’s sterol binding
pocket and the hydrophobic environment provided by α-helices
2, 3, and 4 (Figure 4). Two regions of STARD1 appear important
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FIGURE 3 | STARD1 activity and quantification. COS-1 cells were
cotransfected with the F2 construct (Harikrishna et al., 1993) (500 ng) and 200
ng pcDNA3.1 harboring the wild type (WT) human STARD1 cDNA. (WT
STARD1-pcDNA3.1) or the mutant L275P STARD1-pcDNA3.1 and 300 ng of
pcDNA3.1. Cells were incubated for 24 h. (A) 20µg of whole cell homogenate
were analyzed by immunoblotting. The membranes were exposed to anti-
STARD1 antibody, followed by a horseradish peroxidase-conjugated
anti-rabbit secondary antibody (Fleury et al., 2004). Immunoreactive proteins
were visualized with ECL Plus (Amersham Biosciences, U.K. Ltd., Little
Chalfont, Buckinghamshire, England) on a Storm 860 laser scanner instrument
(Molecular Dynamics, Sunnyvale, CA) and the band intensity was quantified
using ImageQuant software. (B) Pregnenolone from cell media was analyzed
by radioimmunoassay (Fleury et al., 2004). Results are expressed as STARD1
activity/STARD1 quantity after background subtraction.
for the binding of cholesterol and its release during its transfer to
the IMM. A cholesterol gating region containing the C-terminal
α-helix 4 and a cholesterol binding region buried inside the
STARD1 molecule (Roostaee et al., 2008). More specifically,
the importance of STARD1’s C-terminal region in cholesterol
transfer is confirmed by many observations; deletion of 28
amino acids from the C-terminal results in a complete loss of
steroids production (Arakane et al., 1996;Wang et al., 1998). This
C-terminal deletion corroborates with the truncated STARD1
mutant Q258X and lead to LCAH (Miller, 1997).
In vitro experiments have highlighted the role of α-helix
4 as a gate for cholesterol binding (Baker et al., 2005;
Roostaee et al., 2008). The helix would be in thermodynamic
equilibrium between a partially-unfolded (open) and folded
(closed) states (Mathieu et al., 2002a). Upon cholesterol binding,
the equilibrium is shifted to the more stable closed state (Baker
et al., 2005; Roostaee et al., 2008; Barbar et al., 2009a), until
the subsequent release of the ligand by other mechanisms, such
as interactions with other mitochondrial proteins, to trigger the
transfer of cholesterol from the outer to the inner mitochondrial
membrane (Liu et al., 2006; Bose et al., 2008a).
The hypothesis is that the STARD1 C-terminal α-helix 4
movement is a key factor for STARD1-mediated cholesterol
transfer inside mitochondria (Mathieu et al., 2002a,b; LeHoux
FIGURE 4 | Molecular model of STARD1 L275P mutation. (A) The
essential elements of the wild-type STARD1 are shown. The salt bridge formed
by Glu169/Arg188 putatively interacts with the β-OH of cholesterol, while the
α-helix 4 is in a closed state. The line of hydrophobic residues
Phe267/Leu271/Leu275 interacting with α-helix 2, Met225 and other
hydrophobic residues (not shown for image simplicity) help stabilize the
STARD1 /cholesterol complex. (B) The long hydrophobic side chain for Leu275
is absent in the clinical mutation L275P, thereby creates a void in the
hydrophobic environment necessary for stabilizing holo- STARD1, leading to a
reduction in cholesterol binding and steroidogenic activity (Roostaee et al.,
2008). Initial coordinates for the molecular modeling of STARD1 were retrieved
from the Protein Databank (code 1IMG). Site-directed mutagenesis and energy
minimization were done in silico using the molecular modeling software SYBYL
8.0 (Tripos Inc, St. Louis, MO). All the rendering was done using PYMOL
(DeLano, W. L. The PyMOL Molecular Graphics System, 2002, DeLano
Scientific, Palo Alto, CA).
et al., 2003). For instance, biochemical and structural studies of
the L275P mutation at the α-helix 4 led to a dramatic reduction
in cholesterol binding that correlated with a decrease in the
steroidogenic activity of STARD1 (Roostaee et al., 2008).
Several amino acids are in contact with the sterol binding
pocket. Figure 4A shows Leu275 and other residues forming a
hydrophobic core near the end of the C-terminal α-helix 4, and
Figure 4B shows the model for the mutation Leu275 to proline.
Any alterations in these residues, forming a line of hydrophobic
residues, would affect the binding and the steroidogenic activity
of STARD1. In the case of the L275P mutation, it yielded a 13%
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pregnenolone production in isolated mitochondria (Roostaee
et al., 2008); such a level of steroidogenesis is in agreement with
previous studies (Bose et al., 1996; Khoury et al., 2004).
The far-UV CD spectra of STARD1 WT has a 32.5% α-
helical content, which is close to the 40% maximum helical
content calculated for the three-dimensional model. The L271N
and L275P mutants showed a reduced α-helical content of
28.8 and 29.4% respectively compared with STARD1 WT.
As discussed above, these mutants were expected to lead to
the weakening of the hydrophobic interface and hence to a
reduction in the amount of α-helical content and stable tertiary
structure (Roostaee et al., 2008). Also, short molecular dynamics
simulations have indicated that the L275P mutation confers a
higher flexibility to STARD1’s α-helix 4 (Barbar et al., 2009b),
which suggests a more open state of the helix, thereby reducing
its gating capacity, which is related to the decrease in cholesterol
binding and the steroidogenic activity previously studied (Bose
et al., 1998; Roostaee et al., 2008).
Interestingly, another clinical leucine to proline mutation
(L260P) at the α-helix 4 has been found in Swiss LCAH patients
and exhibited a similar in vitro steroidogenic activity as the L275P
mutant (Flück et al., 2005). Hence, one would expect that the
L260P mutant might structurally behave in a similar fashion as
L275P, by affecting the α-helix 4 gating mechanism.
FUNCTIONAL ACTIVITIES
Functional activities determined in transfected COS-1 cells
revealed differences between different mutants. On the two
LCAH patients reported in the study of Lin et al. (1995), the
Q258X STARD1 mutant had a functional activity of 17% and
the R193X mutant had 14%. Bose et al. reported that the
L275P mutant converted 10% more cholesterol to pregnenolone
than the vector control (Bose et al., 1996). In 19 Japanese
patients, Nakae et al. reported 8 different mutations and in
functional studies only the M225T mutation was found to
have a partial activity of 44% (Nakae et al., 1997). All other
mutants had activities not greater than that of the vector plasmid.
STARD1-independent pregnenolone production in the three
above mentioned studies was about 14%. Nakae et al. reported
on a patient with Q258X, M225T (heterozygous compound)
mutations who had a cliteromegaly at the time of diagnosis
and moderate elevation of serum testosterone in response to
hCG stimulation (Nakae et al., 1997). This patient had the onset
of symptoms of adrenocortical insufficiency at the age of 10
months. These authors suggested that late onset of LCAH results
from mutations that do not completely inactivate STARD1. The
Canadian patient cited by Bose et al. (1996) had the heterozygous
compound mutation A218V, L275P, and 46,XY karyotype; her
manifestations of corticosteroid deficiency were noted at the age
of 2 months.
STARD1 INDEPENDENCE
STARD1 is mainly expressed under acute tropic hormone
stimulation. In the absence of STARD1, several elements may
account for the basal level of steroid hormone production. For
example, MLN64 may be able to enhance the basal low level
of steroidogenesis since it is present in human granulosa and
theca cells as well as in the fetal adrenal cortex (Watari et al.,
1997). Other proteins with a START domain (like STARD4 and
D6) might contribute to the basal steroidogenic activity (Soccio
et al., 2002; Bose et al., 2008b), but their precise distribution
in steroidogenic tissues and role are yet to be clarified. The
synthesis or uptake of hydroxysterols might also contribute to the
STARD1-independent steroidogenesis; for example, soluble 22R-
OH and 25OH-cholesterol can diffuse to the innermitochondrial
membrane without the participation of STARD1 and be used as
substrate for pregnenolone formation (Lin et al., 1995; Roostaee
et al., 2008).
LCAH AND STARD1 MUTATION IN
CANADA
In this review, we report the first detailed study of LCAH
due to homozygous STARD1 mutation in Canada and, to our
knowledge, the first successful pregnancy in a 46,XX female
with this disease. Since the discovery of STARD1 in 1994 (Clark
et al., 1994), many important works contributed to increase
our understanding on the role played by this protein in the
steroidogenesis and the physiology of LCAH. We have identified
a homozygous recessive mutation on the STARD1 gene of our
two patients and the heterozygous mutation in their mother and
father. This mutation resulted in the substitution of a leucine by
a proline (L275P) in the STARD1 protein (Khoury et al., 2004),
which did not conserve more than 13% of its steroidogenesis
activity compared to wild type STARD1, as analyzed in COS-
1 cells. This is in agreement with Bose et al. (1996) who
reported that the mutated L275P STARD1, found in another
Canadian, converted 10% more cholesterol to pregnenolone
than the control vector. The Canadian patient cited by Bose
et al. (1996) had the heterozygous compound mutation A218V,
L275P, and 46,XY karyotype; her manifestations of corticosteroid
deficiency were noted at the age of 2 months. We did not have
the opportunity to obtain a genetic history for this patient; we
know however (personal communication from Dr. Rose Girgis,
Edmonton, Canada) that the parents are from French Canadian
origin who lived in the province of Quebec before moving to the
west. It is unknown if any parental connection exists between
these two families who share the allele L275P. Although the
number of patients bearing the L275P mutation is too small to
be conclusive, it might indicate a possible founder effect for this
disease in Canada (Bose et al., 1996).
CLINICAL MANIFESTATION AND
EFFICIENCY OF CHOLESTEROL
TRANSFER SYSTEM
The two patients, A and B, described in this study had a
normal health before their first admission to the hospital
for severe manifestations of mineralocorticoid deficiency and
hyperpigmentation at the age of 11 and 4 1/2months respectively.
Some residual secretion of aldosterone was present and basal
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blood cortisol was in the low normal level, but without any
significant response to ACTH stimulation up to the age of
3 years for patient A and only 15 months for her sister.
Consequently, patient A seemed to have less severe corticosteroid
deficiency than patient B and both patients have less severe
mineralocorticoid and glucocorticoid deficiencies than reported
in similar cases (Bose et al., 1996).
To date, at least 97 patients with LCAH and more than
35 different mutations have been reported in the STARD1
gene (Bhangoo et al., 2005, 2006; Papadimitriou et al., 2006;
Abdulhadi-Atwan et al., 2007). Two distinct genetic clusters
were initially reported: More than 70% of Japanese alleles and
all Korean alleles carry the Q258X mutation; a second genetic
cluster is found among Palestinian Arabs, most of whom carry
the R182L mutation. Many publications underline that some
correlations exist between the severity of STARD1 mutation and
the age of onset of a clinical salt-wasting crisis, hypoglycemia
and gonadal function (Bose et al., 1996; Miller, 1997; Bhangoo
et al., 2005, 2006). Patients with the mutation Q258X or R182L
are generally symptomatic by the age of 1 day to some weeks.
Three unrelated patients of Swiss ancestry, L260P mutant, had
their onset of symptoms at the age 2.5–5.5 months (Flück et al.,
2005). Furthermore, as reported by Chen et al. (2005) patients
from eastern Saudi Arabia who carry the R182H mutation, very
close to the Palestinian mutation R182L, had a milder disease
starting at the age of 1–14 months, and 4 out of 7 of them had
the onset of their symptoms from 7–14 months of age; functional
study in this group showed a complete loss of STARD1 activity.
One patient from Qatar, with R182H mutation, had the onset
of clinical symptoms and laboratory evidence of salt loss at the
age of 3 weeks (Achermann et al., 2001); the in vitro STARD1
activity of this patient was not determined. The patients reported
by Chen et al. (2005) as well as our two patients raise the
question about the different clinical manifestations and time of
onset with the same genetic mutations, in the same ethnic group
or family members and the same geographic region. There is,
clearly, a limited sensitivity of the different functional assays for
determination of STARD1 activity which may explain the poor
correlation frequently observed between the clinical findings and
the results of in vitro studies. There is also a wide spectrum of
heterogeneity in the clinical manifestations and biochemistry,
as well as, the time of onset of different symptoms in LCAH.
However, in our case, since the assays for Patients A and B are
relatively standardized, the sensitivity is the same.
Interestingly, both patients carry the same mutation, yet the
clinical manifestation of LCAH was delayed between them. The
physiological conditions are different from one pregnancy to
another and the demand for different steroids is variable during
fetal development. Indeed, during pregnancy, conditions such
as nutrition, hydration/dehydration, disease and other stress,
may have an influence on steroidogenesis. In addition, the
circumstances of delivery and the neonatal environment may
have different patterns of tropic hormone stimulation which may
modulate the extent of acute steroidogenic demands.
The STARD1 -dependent and STARD1 -independent
steroidogenesis seem to be good descriptive models to explain
the chronology of events in non-placental steroidogenic tissues.
It is not clear however what determines the length of time an
infant with LCAH can survive before experiencing a salt-wasting
crisis (Hauffa et al., 1985; Fujieda et al., 2003; Bhangoo et al.,
2006). We still need more information concerning the function
or loss of function of the mutated STARD1 and what determines
the longevity and efficiency of the STARD1 -independent system.
It is clear, however, that early appeal and continuous stimulation
of steroidogenesis in the gonads (by the hormones hCG, FSH,
LH) and the adrenals (by ACTH and the renin-angiotensin
system) are the starting point initiating the failure of both
systems. In this study, our two patients, Patient A, 46,XY and
Patient B, 46,XX, members of the same family with the same
homozygous (L275P) mutation, have different severity of the
disease and different time of onset of corticosteroid deficiency.
Clinical manifestations and hormonal data prove the severe
deficiency of testosterone secretion in Patient A, the milder
ovary dysfunction in Patient B and the presence of some residual
corticosteroid secretion and progressive post natal adrenal failure
for both.
GONADAL FUNCTION IN LCAH AND 46,XY
GENOTYPE
Patient A in this study is a 46,XY genotype with female
external genitalia and blind vaginal pouch. Figure 1 shows lipid
accumulation in Leydig cells typical of LCAH. The absence of
androgen secretion, basal and after hCG stimulation, as well as
the absence of Wolffian structures testify on the early and severe
deficiency of testosterone secretion necessary for differential
sexual development and virilization. In fact, during the early
weeks of embryonic development, the fetus is exposed to acute
hCG stimulation which may lead to lipid accumulation in the cell
due to the lack of STARD1 activity, thereby destroying Leydig
cells. This is clearly contrasting with the relatively moderate
severity of mineralocorticoid and glucocorticoid deficiency of
this patient. Generally, all 46,XY reported patients had a
profound impairment of testosterone synthesis (Bose et al., 1996),
however Wolffian duct derivatives are sometimes well developed
as reported by Nakae et al. (1997) on patient 7 (Q258X, M225T)
who had a cliteromegaly and moderate secretion of testosterone
in response to hCG stimulation.
This seems to be concordant with the hypothesis of the earlier
mentioned STARD1-dependent steroidogenesis deficiency and
STARD1-independent impairment of steroidogenesis due to
Leydig cells destruction following lipid accumulation caused
by an early and continuous stimulation (placental hCG, fetal
pituitary LH). Such patients should be raised as females (Bose
et al., 1996) and should undergo orchidectomy due to the risk
of in situ testicular carcinoma development (Korsch et al., 1999).
GONADAL FUNCTION IN LCAH AND 46,XX
GENOTYPE
Spontaneous Puberty
Patient B in this study is a unique case. While she had an earlier
and more severe corticosteroid deficiency than her sibling, her
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ovarian function was less disturbed than what was observed
in other similar cases (Bose et al., 1996). By the end of 1990,
at the age of 11 7/12 years, she started a progressive pubertal
development; her ovarian response to hCG stimulation was
normal and she had menarche at the age of 14 2/12 years
(Khoury et al., 2004). This was unexpected for LCAH in 1993.
Our observations are in agreement with Matsuo’s report in 1994
(Matsuo et al., 1994) that 5/5 46,XX patients with LCAH aged
more than 13 years expressed a spontaneous development of
secondary sex characters and vaginal bleeding at the time of
puberty, their estrogen level ranging from 22–85 pg/ml. Bose
et al. (1997) described in 1997 the first genetic analysis in a
46,XX female homozygous for STARD1 shift mutation 2611T
and spontaneous feminization. Three other cases were reported
by Fujieda et al. (1997, 2003)who found that the ovaries of such
patients were enlarged in the post pubertal stage with many cysts
occupying the entire volume of the ovary and with hypertrophied
ovarian stroma. This phenomenon was not observed on repeated
echographies in our Patient B. The heterogeneity in the pubertal
development of 46,XX female patients with STARD1 mutation
was also described by Nakae et al. (1997) who reported on
6/10 46,XX patients who experienced spontaneous pubertal
changes, irregular menstruations, anovulatory cycles and in
some a polycystic aspect of ovaries. All these reports show
that the difference in the extent of impairment of the testis
and ovaries is dramatic in LCAH. However, although initially
unexpected, even the most severely affected 46,XX female
patients undergo spontaneous feminization, breast development
and cyclical vaginal bleeding at the usual age of puberty (Matsuo
et al., 1994; Bose et al., 1997; Nakae et al., 1997).
The fetal ovary cells are quiescent and in affected 46,XX
patients these–cells should remain undamaged since they should
not accumulate cholesterol esters until they first undergo
gonadotropin stimulation. This would explain why these cells
retain steroidogenic capacity and hence at the time of puberty
can make estrogens, albeit, in subnormal amounts, resulting
in high gonadotropin secretion. However, only the cells in
the individually recruited follicles undergo stimulation, and
hence only these cells accumulate cholesterol esters and lose
steroidogenic capacity. Regular monthly cycles are possible,
because a large number of follicles remain relatively undamaged
before recruitment. Such monthly cycles, which may persist for
years, are probably anovulatory and can produce a large quantity
of ovarian cysts.
STARD1 EXPRESSION IN THE OVARIES
The study of Sandhoff and McLean (1996) shows that in
rat ovaries STARD1 mRNA expression is controlled by tropic
hormones PMSG (post-menopausal stimulating gonadotropin)
and hCG. hCG increases the steady-state level of STARD1
mRNA in the ovary during follicular and luteal development.
The rise in STARD1 expression paralleled the rise in serum
progesterone levels, consistent with STARD1’s presumed role
in the regulation of steroidogenesis. Furthermore. STARD1
gene expression in primary cultures of porcine granulosa cells
is stimulated above control levels by FSH, 8-bromo-cAMP
and IGF-1 respectively. FSH and IGF-1 interact synergistically
to induce amplification of STARD1 mRNA and protein
expression in serum-free monolayer culture of immature swine
granulosa cells (Balasubramanian et al., 1997). During follicular
development in the rat ovary, Ronen-Fuhrmann et al. (1998)
have examined the time-dependent expression of STARD1
mRNA and protein in PMSG/hCG-treated immature rats. They
found that in the early phase, before the administration of
tropic hormones, granulosa cells did not express STARD1.
The first peak of STARD1expression was generated by PMSG
administration. The expression was restricted to the ovarian
secondary interstitial tissue as well as to a fewer scattered theca
interna cells producing androgens which can synergistically
potentiate FSH-induced actions in granulosa cells, and P450
aromatase for estrogen production in granulosa cells of Graafian
follicles. This also seems to initiate the transition of follicles
from the small antral stage to the preovulatory stage. After
hCG administration, both the granulosa (until now devoid
of STARD1) and the theca-interstitial cell types joined in
synchronized production of STARD1. At this phase of follicular
development, usually perceived as the onset of the luteinization
process, high STARD1mRNA levels resumed in the all-ovarian
interstitium and high levels of STARD1were also expressed in
the granulosa cells; however, in the later cell type, STARD1
expression was strictly confined to periovulatory follicles.
INDUCTION OF OVULATION
The measurement of blood FSH, LH, E2, and other hormones,
at different ages in patient B, argues for a normal function of the
hypothalamus-pituitary axis with a progressive increase of 17β-
estradiol secretion to induce progressive pubertal feminization
and regular menstruations. This was probably due to an
efficient mechanism of STARD1 -independent steroidogenesis
still undamaged by the toxic accumulation of cholesterol and its
derivatives, during the short life of stimulated follicles. However,
data showed that she failed to demonstrate the spontaneous
estrogen surge of the end of follicular phase, necessary for the
secretion of ovulatory peak of LH, ovulation and consequently
the normal increase of progesterone and basal temperature
during the next theoretical luteal phase. The menstrual cycles of
this patient were anovulatory for many years before consulting
for infertility problems. Interestingly, during her early pubertal
development, a hCG stimulation test resulted in a small
increase in androstenedione and substantial enhancement of
17β-estradiol secretion (Khoury et al., 2009).
The mechanism of this response is subject to speculation,
but more importantly it indicates that the steroidogenic systems
retained some capacity to respond to tropic hormones. Thus,
during the follow-up in the fertility clinic, we proposed to
observe the function of the hypothalamus-hypophyso-ovarian
axis during a Clomiphene stimulation test. This was done
at the age of 25 years. Endocrine data shows that pituitary
gonadotrophins, induced by Clomiphene stimulation, enhanced
the steroidogenesis process in the granulosa cells, in the same
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manner as was observed with the hCG stimulation test, 13 years
earlier. Furthermore, the high levels of progesterone and 17β-
estradiol observed during the second half of her menstrual cycle
is a clear confirmation of a process of ovulation and luteinization
(Khoury et al., 2006b, 2009). According to Ronen-Fuhrmann
et al. (1998) this is due, in the normal rat, to the high STARD1
expression induced by tropic hormones in all ovarian interstitium
and the granulosa cells of periovulatory follicles. In our patient,
this may indicate that hCG stimulation or increased secretion
of pituitary FSH and LH induced by Clomiphene, as well as the
ovulatory peak of LH, may have a role of further activation of
the STARD1-independent system (Watari et al., 1997). It is also
plausible to think that the amplification of the mutated STARD1
expression by those tropic hormones may contribute, via its
partial steroidogenic activity, to the production of estrogen surge
necessary for the ovulatory peak of LH and ovulation.
STARD1, CORPUS LUTEUM, AND
PREGNANCY
Pregnancy is the ultimate proof of the induction of ovulation.
In our patient this was produced by Clomiphene stimulation.
We believe that any other protocols of ovulation induction
by gonadotrophins will also have a good chance of success.
Our patient had a first pregnancy at the age of 25 4/12
years. However, a spontaneous abortion occurred 6 weeks later.
The human corpus luteum derived from the ovulated follicle
is an active producer of progesterone, an essential hormone
for establishing and sustaining early pregnancy (Carr, 1992).
Placental progesterone becomes sufficient to maintain pregnancy
only after about 6 weeks of gestation, the so-called “luteoplacental
shift.” Consequently, human maternal ovariectomy in the
first 6 weeks will cause spontaneous abortion, but maternal
ovariectomy thereafter will not (Csapo et al., 1973; Csapo
and Pulkkinen, 1978). The critical step in luteal progesterone
secretion is the movement of cholesterol from the OMM to
the IMM (Devoto et al., 2002). Examination of corpora lutea
of different luteal phases revealed that the basal expression of
STARD1 transcript and protein was greatest in early and mid-
luteal phase to decline in the late-luteal phase. Furthermore,
under hCG stimulation, the expression of the major 1.6 kb
STARD1 mRNA transcript is rapidly enhanced. The rise in
STARD1 expression paralleled an increase in progesterone levels
(Chung et al., 1998; Devoto et al., 2001). In human corpus
luteum, the theca-lutein cells and granulosa-lutein cells exhibited
marked heterogeneity in STARD1 protein concentration, with
theca-lutein cells expressing greater levels of STARD1 than
granulosa-lutein cells, irrespective of the stage of the luteal
phase (Devoto et al., 2001; Christenson and Devoto, 2003).
Human chorionic gonadotropin treatment during the late-
luteal phase causes a pronounced increase in both theca-and
granulosa-lutein cell STARD1 gene expression. In some species,
including human, PGF2α is believed to be the physiological agent
responsible for causing corpus luteum regression at the end of
a non-fertile cycle. This luteolytic compound has been shown
to cause a pronounced decline in STARD1 gene expression,
altering cholesterol transport to the mitochondria, inhibiting
progesterone production and leading to substantial stores of
lipids (Devoto et al., 2001; Christenson and Devoto, 2003). The
distribution of STARD1 inside theca and granulosa-lutein cells
of human corpus luteum was assessed by electron microscopy
(Sierralta et al., 2005). Greater levels of STARD1 immunolabeling
was found in the cells from early- and mid- than in the late-
luteal phase of corpus luteum, and lower levels in cells from
women treated with GnRH antagonist in the mid-luteal phase.
There is also a substantial amount of mature STARD1 protein (30
kDa) in the cytoplasm of luteal cells (Sierralta et al., 2005). The
presence of STARD1 in the cytoplasm was also reported in rat
adrenal homogenates (LeHoux et al., 1999). The administration
of GnRH antagonist during mid-luteal phase causes a dramatic
reduction in STARD1 immunolabeling in both the cytosol and
mitochondria of theca and granulosa-lutein cells of mid-luteal
corpus luteum suggesting that, the levels of STARD1 protein in
both cell compartments are LH dependent. Also, the presence
of MLN64 in the supernatant of human corpus luteum extract
throughout the luteal phase (Watari et al., 1997; Kishida et al.,
2004) supports the idea that in cells with high steroidogenic
activities, proteins with a START domain, other than STARD1,
might participate in the intracellular trafficking of cholesterol or
other lipids.
We conclude that the early spontaneous abortion at the
first pregnancy was due to a dysfunction of this mutated
STARD1 inside the theca and granulosa cells of the corpus
luteum. The STARD1-dependent steroidogenesis was highly
solicited during the early and middle phase of the corpus
luteum development by an acute and important stimulation
of hCG. The incapacity of the mutated STARD1 to transport
the high quantity of cholesterol to the IMM will result in an
accumulation of cholesterol, cholesterol esters, and oxidative
products in the steroidogenic cells of the corpus luteum. This
leads to the destruction of both the STARD1-dependent and
STARD1-independent systems, in agreement with the two-hit
theory concerning STARD1mutations in steroidogenic tissues.
Moreover, this explains the failure of the corpus luteum to
produce the progesterone necessary for preparing and stabilizing
the endometrium, and protecting the embryo during the
early first trimester (Christenson and Devoto, 2003; Sierralta
et al., 2005). Substitution therapy with progesterone was then
indicated. It was recommended to start progesterone at the 17th
day of the cycle and to continue this treatment, during the
first trimester, if pregnancy was confirmed later. This technique
was successful since a second pregnancy occurred. Progesterone
treatment was initially recommended throughout the pregnancy
hoping to optimize uterine quiescence and prevent premature
delivery in her multiple gestations (Meis, 2005); but for some
reason, it was stopped at 25 weeks. Delivery of two normal boys
occurred at 30 weeks of gestation. The same treatment was used
for a third pregnancy, however progesterone administered up to
the 17th week was deemed sufficient to support a single gestation.
This led to the delivery of a normal girl at 36 weeks of gestation
(October 2008).
In 2008, Sertedaki et al. reported a female LCAH patient
bearing a 11-bp deletion in exon 6 of her STARD1 gene (Sertedaki
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et al., 2009). She did have “cysts in the ovaries” and the
LH/FSH ratio was very high. After many unsuccessful attempts
to conceive, she entered a program of IVF. Follicle development
and growth was easily obtained by the administration of
recombinant FSH and recombinant LH and follicle maturation
was initiated by hCG administration before oocyte retrieval. After
IVF and implantation, vaginal administration of progesterone
was conducted to support pregnancy up to the 11th week.
A female baby was born by cesarean section in 2007 with
no perinatal complications. The used protocol was a classic
strategy for IVF. Furthermore, it is fully concordant with our
strategy for induction of ovulation and protecting pregnancy
in LCAH during the first trimester of gestation. In our case,
we used Clomiphene for ovulation induction and only 400–
600mg/d of progesterone (Prometrium) (oral and/or vaginal)
was given (Smitz et al., 1992; Progesterone supplementation,
2008).
PREGNANCIES OBSERVATIONS
Ovulation induction with Clomiphene citrate is associated, in 6–
8 % of cases, with multiple pregnancies, mainly twins (Messinis,
2005). During her last two pregnancies, the patient B developed
high blood pressure. Because it first started during pregnancy and
it returned to normal after delivery, we classified it as gestational
hypertension. She never met preeclampsia criteria. The onset
of high blood pressure was earlier in the second pregnancy
(16+ 6 weeks GA) than in the third one (34 weeks GA), perhaps
because of the twin pregnancy status which represents a risk
factor (Creasy et al., 2004).
We do not know exactly the cause of the two preterm
deliveries preceded by premature preterm rupture of membranes
(PPROM). Although high dosages and regular daily oral steroid
administration during pregnancy has been associated with
preterm delivery and PPROM (Laskin et al., 1997), this was
FIGURE 5 | Cellular model of steroidogenesis and LCAH. Low and high density lipoproteins (LDL and HDL) are captured by receptors on the cell membrane.
Initial metabolism of LDL lipids occurs in the lysosome where cholesteryl esters are hydrolyzed by acidic cholesteryl ester hydrolases (acidic CEH). The resulting free
cholesterol (Ch) is re-esterified by the cytosolic acyl-CoA:cholesterol acyltransferase (ACAT) and stored in lipid droplets. Cholesterol can also be synthesized de novo
in the endoplasmic reticulum. In the resting cell, cholesterol is constantly hydrolyzed/re-esterified by neutral CEH and ACAT. With the help of lipid transporters, free
cholesterol can be conveyed at the OMM. Then cholesterol present at the OMM can be transferred to the IMM for conversion to pregnenolone without STARD1. This
low capacity system may explain the basal level of hormone production (10–13%) for homeostasis. Following an acute event (stress, dehydration, puberty, etc.), tropic
hormones stimulate steroidogenic cells and activate PKA, which in turn leads to three actions: The activation of the hormone-sensitive lipase (HSL) which releases
cholesterol from lipid droplets, the de novo synthesis of STARD1, and the formation of a multiprotein complex (MPC) somehow involved in the transfer of cholesterol to
the IMM (Liu et al., 2006; Bose et al., 2008a). Then STARD1 may act as a high capacity system by catalyzing the delivery of cholesterol to the OMM and the MPC
complex for its transfer to P450scc in response to the acute demand for steroid hormones. In the case of LCAH, the STARD1 high capacity system is impaired cannot
support the substantial throughput of cholesterol, and the latter accumulates in the cytosol; lipid droplets become engorged with cholesterol. As lipid droplets
accumulate, the cell becomes less functional and LCAH is onset.
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probably not the case for our patient who received physiological
doses of hydrocortisone and fludrocortisone acetate during her
pregnancies. Furthermore, in this case, we not believe that there
is an association between preterm delivery from PPROM and
cessation of progesterone, since the patient did not complain of
premature contraction or significant uterine activity before the
delivery. Also, stimulation with oxytocine has been necessary for
delivery. Finally, even if infection is a main causative agent in
PPROM, she didn’t have any criteria associated with that.
CONCLUSION
We have described clinical data collected over 38 years of follow-
up on two French-Canadian patients with 46,XY and 46,XX
karyotype and presenting the classical clinical manifestations of
LCAH due to a homozygous STARD1 mutation (L275P).
The two patients presented the classic picture of LCAH.
Mineralocorticoids and glucocorticoids deficiencies are less
severe in Patient A than Patient B. Both patients have had less
severe manifestations of corticosteroid deficiency and a later
onset of clinical symptoms than the vast majority of patients
suffering from STARD1 mutations described in the literature.
Patient A (46,XY) portrayed clinical and biochemical signs of
early and severe deficiency of testosterone secretion. Testosterone
is necessary for differential sexual development and virilization in
the early weeks of fetal life during the period of high stimulation
by hCG.
Patient B, 46,XX karyotype, is probably one of the first patients
with LCAH in which spontaneous pubertal development was
observed. She had menarche and spontaneous regular non-
ovulatory menstruations for many years before consulting the
fertility clinic. hCG and Clomiphene stimulation tests proved
the possibility of increasing estrogen secretion by an acute
stimulation of the ovarian theca interstitia and the granulosa
cells. Clomiphene stimulation restored the surge of 17β-estradiol
and LH secretion of the mid-cycle to induce ovulation and open
the door for pregnancy. Our understanding of the physiological
role of STARD1 during the different phases of the corpus
luteum was essential to explain the miscarriage at 6 weeks of
the first pregnancy, and then to develop a preventive therapy
by progesterone administration during the first trimester of the
following pregnancies. We were able to describe and present
the first case of pregnancy in the patient with LCAH. It was a
very long way from a fatal disease to a normal healthy life and
restoration of the reproductive function in a female with the
L275P mutation of STARD1.
The clinical and biochemical data of our two patients
are concordant with the STARD1-dependent and STARD1
-independent mechanisms of steroidogenesis. However, the
non-STARD1 steroidogenesis system is, in our opinion,
the basal physiologic system of steroid synthesis producing
normal adrenal and gonadic steroids during the normal
physiological circumstances. Furthermore, the STARD1 -
dependent steroidogenesis system seems to be a key rate-limiting
mediator in the acute regulation of steroidogenesis by tropic
hormones. It is acting during the acute need for more production
of steroids during physiologic periods of normal development
(as sexual differentiation and virilization in the early fetal life of
the male), surgical or infection stress, normal surge of estrogen
production in the mid-cycle necessary for ovulation, or the
high production of progesterone during the first trimester of
pregnancy. The incapacity of the mutated STARD1 to assume
this high speed function, during stress situations and tropic
hormone stimulation, leads to the accumulation of high levels
of cholesterol, cholesterol esters and oxidative products in the
cell. Early appeal and continuous stimulation of steroidogenesis
in the gonads (by the hormones hCG, FSH, LH) and the
adrenal (by ACTH and renin-angiotensin system) are the
starting points initiating the failure of both systems of steroid
production.
Figure 5 shows an up to date model of steroidogenesis and
LCAH. Despite all the progress made during the last 20 years
in the physiology of the transfer of cholesterol to the IMM
(Liu et al., 2006; Bose et al., 2008a; Miller, 2016), we still need
to understand the detailed interplay between STARD1 and its
delivery of cholesterol to a multiprotein complex (MPC) (Liu
et al., 2006; Bose et al., 2008a) somehow involved in the transfer
of cholesterol to the IMM.
Finally, we wish to point the reader to our recent progress on
the dynamics andmechanism of ligand binding and release of the
START domain of STARD6 (Létourneau et al., 2016).
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